Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1983 2
1984 2
1985 1
1987 3
1988 2
1989 2
1990 1
1991 1
1992 2
1993 2
1994 6
1995 3
1996 3
1997 4
1998 3
1999 4
2000 3
2001 3
2003 5
2004 14
2005 11
2006 8
2007 4
2008 12
2009 8
2010 10
2011 14
2012 9
2013 6
2014 11
2015 7
2016 7
2017 7
2018 6
2019 3
2020 9
2021 11
2022 6
2023 3
2024 2
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Alfacalcidol vs Calcitriol in the Management of Patient With Hypoparathyroidism: A Randomized Controlled Trial.
Saha S, Sreenivas V, Goswami R. Saha S, et al. J Clin Endocrinol Metab. 2021 Jun 16;106(7):2092-2102. doi: 10.1210/clinem/dgab114. J Clin Endocrinol Metab. 2021. PMID: 33616655 Clinical Trial.
CONTEXT: Alfacalcidol and calcitriol are commonly used for managing hypoparathyroidism. Their relative merits have not been systematically assessed. ...SUBJECTS AND METHODS: IH patients with optimal calcemic control on alfacalcidol were continued on the same (n = 20 …
CONTEXT: Alfacalcidol and calcitriol are commonly used for managing hypoparathyroidism. Their relative merits have not been systemati …
Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial.
Oka T, Sakaguchi Y, Isaka Y, Ishii H, Kabata D, Shintani A, Nakatani S, Morioka T, Mori K, Inaba M, Emoto M, Shoji T. Oka T, et al. Sci Rep. 2022 Sep 14;12(1):15463. doi: 10.1038/s41598-022-19820-2. Sci Rep. 2022. PMID: 36104443 Free PMC article. Clinical Trial.
Because the cardiovascular effect of alfacalcidol could be modulated by bone turnover status, this post-hoc analysis of the J-DAVID examined how alkaline phosphatase (ALP), a more precise marker of bone turnover than parathyroid hormone (PTH), modifies the impact of alf …
Because the cardiovascular effect of alfacalcidol could be modulated by bone turnover status, this post-hoc analysis of the J-DAVID e …
Dialysate calcium, alfacalcidol, and clinical outcomes: A post-hoc analysis of the J-DAVID trial.
Iseki K, Kabata D, Shoji T, Inaba M, Emoto M, Mori K, Morioka T, Nakatani S, Shintani A. Iseki K, et al. PLoS One. 2022 Sep 7;17(9):e0273195. doi: 10.1371/journal.pone.0273195. eCollection 2022. PLoS One. 2022. PMID: 36070301 Free PMC article. Clinical Trial.
We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol. The trial was an open-label randomized clinical trial including 976 HD patients with intact PTH of 180 pg/mL or lower which compared the user …
We examined the trajectories of CKD MBD parameters among the J-DAVID trial participants to see the effect of D-Ca and alfacalcidol. T …
Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T. Soen S, et al. J Bone Miner Metab. 2020 Jul;38(4):511-521. doi: 10.1007/s00774-019-01077-x. Epub 2020 Jan 22. J Bone Miner Metab. 2020. PMID: 31970477 Clinical Trial.
INTRODUCTION: This study compared the clinical usefulness of minodronate (50 mg/4 weeks) plus alfacalcidol (1 mug/day) (Group M) with that of alfacalcidol alone (1 mug/day) (Group A) for treating glucocorticoid-induced osteoporosis. ...In Group M, both bone formatio …
INTRODUCTION: This study compared the clinical usefulness of minodronate (50 mg/4 weeks) plus alfacalcidol (1 mug/day) (Group M) with …
Clinical effect of alfacalcidol in children with Henoch-Schonlein purpura: a prospective randomized controlled trial.
Fu Q, Shi MF, Chen Y. Fu Q, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2021 Aug 15;23(8):797-801. doi: 10.7499/j.issn.1008-8830.2105136. Zhongguo Dang Dai Er Ke Za Zhi. 2021. PMID: 34511168 Free PMC article. Clinical Trial. Chinese, English.
OBJECTIVES: To study the effects of alfacalcidol on serum 25-(OH)D(3) level, cellular immune function, and inflammatory factors in children with Henoch-Schonlein purpura (HSP). ...OBJECTIVE: To study the effects of alfacalcidol on serum 25-(OH)D(3) level, cellular i …
OBJECTIVES: To study the effects of alfacalcidol on serum 25-(OH)D(3) level, cellular immune function, and inflammatory factors in ch …
Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. Matsumoto T, et al. J Bone Miner Metab. 2020 Jul;38(4):522-532. doi: 10.1007/s00774-020-01091-4. Epub 2020 Mar 5. J Bone Miner Metab. 2020. PMID: 32140784 Clinical Trial.
This study was undertaken to compare the effect of eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. MATERIALS AND METHODS: A randomized, open-label, parallel group study was conducted to identify the effectiveness and safety of monotherapy with 0 …
This study was undertaken to compare the effect of eldecalcitol on BMD and fracture with that of alfacalcidol in GIO patients. MATERI …
Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis.
Shiraki M, Fukuchi M, Kiriyama T, Okamoto S, Ueno T, Sakamoto H, Nagai T. Shiraki M, et al. J Bone Miner Metab. 2004;22(4):352-9. doi: 10.1007/s00774-004-0494-2. J Bone Miner Metab. 2004. PMID: 15221494 Clinical Trial.
To evaluate the effects of alfacalcidol on bone turnover in elderly women with osteoporosis, an open-label, prospective, calcium-controlled study was conducted. ...Although the changes in bone turnover markers in group D were slight, significant reduction in bone turnover …
To evaluate the effects of alfacalcidol on bone turnover in elderly women with osteoporosis, an open-label, prospective, calcium-cont …
Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients.
Dörr K, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Beitzke D, Hödlmoser S. Dörr K, et al. Cardiorenal Med. 2023;13(1):332-341. doi: 10.1159/000533899. Epub 2023 Sep 20. Cardiorenal Med. 2023. PMID: 37729887 Free PMC article. Clinical Trial.
METHODS: This is a post hoc analysis of the EtECAR-HD trial, where 62 patients were randomized to ETL or alfacalcidol (ALFA) for 1 year. LA volume index (LAVI) was measured using cardiac magnetic resonance imaging. ...
METHODS: This is a post hoc analysis of the EtECAR-HD trial, where 62 patients were randomized to ETL or alfacalcidol (ALFA) for 1 ye …
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW; STOP Investigators. de Nijs RN, et al. N Engl J Med. 2006 Aug 17;355(7):675-84. doi: 10.1056/NEJMoa053569. N Engl J Med. 2006. PMID: 16914703 Free article. Clinical Trial.
A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacalcidol (1 microg) and a placebo tablet of alendronate daily. The primary outcome was the change in bone mineral density of the lumbar spi …
A total of 201 patients were assigned to receive either alendronate (10 mg) and a placebo capsule of alfacalcidol daily or alfacal …
Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily.
Dukas L, Bischoff HA, Lindpaintner LS, Schacht E, Birkner-Binder D, Damm TN, Thalmann B, Stähelin HB. Dukas L, et al. J Am Geriatr Soc. 2004 Feb;52(2):230-6. doi: 10.1111/j.1532-5415.2004.52060.x. J Am Geriatr Soc. 2004. PMID: 14728632 Clinical Trial.
OBJECTIVES: To study the effect of alfacalcidol (1alpha(OH)D3) on fall risk in community-dwelling elderly men and women. DESIGN: Randomized, double-blind, placebo-controlled intervention trial. ...Alfacalcidol treatment was also, independent of total calcium intake, …
OBJECTIVES: To study the effect of alfacalcidol (1alpha(OH)D3) on fall risk in community-dwelling elderly men and women. DESIGN: Rand …
197 results